Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00796783 · ClinicalTrials.gov registry record
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
A clinical trial, sponsored by Corcept Therapeutics.
- Terminated
- Registry status
- 2
- Enrollment target
NCT00796783 is a clinical trial that was terminated before completion, run by Corcept Therapeutics. The registered enrollment target is 2 participants.
The verdict
NCT00796783 was terminated before completion, sponsored by Corcept Therapeutics.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest symptoms and signs of hypercortisolemia.
Interventions
- DRUG Cushing's syndrome confirmation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00796783
The ClinicalTrials.gov registry entry for NCT00796783 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cushing's syndrome confirmation is the first listed.
NCT00796783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00796783 about?
NCT00796783 is a clinical study titled "A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia". This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest symptoms and signs of hypercortisolemia.
What is the current status of trial NCT00796783?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2009-02.
What interventions are being tested in trial NCT00796783?
The interventions under investigation include: Cushing's syndrome confirmation (DRUG).
Who is sponsoring clinical trial NCT00796783?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.